48 completed, 4 recruiting, 3 not yet recruiting, 1 active not recruiting. 59 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 59 | Completed 48, Recruiting 4, Not yet recruiting 3, Active not recruiting 1, Enrolling by invitation 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Enrolling by invitation 1 |
Follow Dyslipidemia: new trials by email Literature Review of Dyslipidemia trials Research Report on Dyslipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10582 in Healthy Subjects and Subjects With Mildly Elevated LDL-C Levels HS-10582, Placebo - Dyslipidemia | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 76 | 2026-09-30 | 2026-08-20 |
| Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers Test Drug, Reference Drug - Hypercholerolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 61 | 2026-08-06 | 2026-09-09 |
| A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers Investigational Product 1, Investigational Product 2, Investigational Product 1 + Investigational Product 2 - Hypertension, Dyslipidemia | Phase 1 | Recruiting | Korea United Pharm. Inc. | 36 | 2026-07-01 | 2026-07-06 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults Test Drug, Reference Drug - Hypercholesterolemia, Dyslipidemia | Phase 1 | Completed | AJU Pharm Co., Ltd. | 41 | 2026-06-11 | 2026-07-10 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C AD-231, AD-231A, AD-231D and AD-231C - Dyslipidemia, Hypertension | Phase 1 | Not yet recruiting | Addpharma Inc. | 60 | 2026-06-01 | 2026-05-15 |
| A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers treatment A, treatment B, treatment C - Dyslipidemia | Phase 1 | Recruiting | Korea United Pharm. Inc. | 50 | 2025-08-12 | 2025-09-09 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects Drug：HS-10510；, Drug：Placebo, Drug： Rosuvastatin - Dyslipidemia | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 88 | 2025-06-01 | 2025-06-03 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia AZD4954, Placebo - Healthy Participants, Dyslipidemia | Phase 1 | Recruiting | AstraZeneca | 171 | 2025-05-27 | 2026-11-02 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults Test Drug, Reference Drug - Dyslipidemia | Phase 1 | Active not recruiting | AJU Pharm Co., Ltd. | 60 | 2025-05-24 | 2025-06-12 |
| Study to Evaluate the Safety and the Pharmacokinetics of "UI111" and "UIC202006" Under Fed Conditions Administration of UI111, Administration of UIC202006 - Dyslipidemia | Phase 1 | Completed | Korea United Pharm. Inc. | 44 | 2025-02-13 | 2026-07-08 |
| ALN-APOC3 in Adult Participants With Dyslipidemia ALN-APOC3, Matching Placebo - Dyslipidemia | Phase 1 | Completed | Regeneron Pharmaceuticals | 32 | 2025-01-27 | 2026-03-16 |
| A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C. AZD0780, Ezetimibe, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 81 | 2024-12-20 | 2025-11-10 |
| A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects HRS-5632, Placebo - Dyslipidemia | Phase 1 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 50 | 2024-12-02 | 2026-04-03 |
| Clinical Study to Evaluate Drug-drug Interaction and Safety After Co-administration of D352 and D794 in Healthy Adult Volunteers D352, D794 - Dyslipidemia | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 40 | 2024-11-27 | 2025-05-21 |
| Improving Cardiovascular Health Risks in Adults With Epilepsy on a Modified Atkins Diet Atorvastatin 10mg, Modification of dietary fat composition - Epilepsy, Dyslipidemia | Phase 1 / Phase 2 | Enrolling by invitation | Johns Hopkins University | 22 | 2024-10-04 | 2026-10-19 |
| A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects RS-C1001, placebo, Placebo - Dyslipidemia | Phase 1 | Recruiting | Peking University First Hospital | 72 | 2024-09-25 | 2024-11-01 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. AZD0780, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 16 | 2023-03-09 | 2025-04-27 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects AZD0780, Placebo, Rosuvastatin - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 183 | 2022-05-18 | 2026-09-09 |
| A Study of AZD8233 in Participants With Dyslipidemia. Part A:Placebo, Part A:AZD8233, Part B:Placebo - Dyslipidemia | Phase 1 / Phase 2 | Completed | AstraZeneca | 87 | 2021-01-20 | 2024-12-24 |
| To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia AZD8233 subcutaneous injection, Placebo - Dyslipidemia | Phase 1 | Completed | AstraZeneca | 34 | 2019-11-21 | 2021-06-30 |
Showing 20 of 59. Sign in to see all of them.
Dyslipidemias (59) · Hypercholesterolemia (9) · Cardiovascular Diseases (4) · Diabetes Mellitus, Type 2 (4) · Hypertension (3) · Obesity (2) · Acute Coronary Syndrome (1) · Arachnodactyly (1) · Atherosclerosis (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Epilepsy (1) · Hepatic Insufficiency (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1)
Lipid Metabolism Disorders (59) · Nutritional and Metabolic Diseases (59) · Metabolic Diseases (58) · Hyperlipidemias (9) · Endocrine System Diseases (5) · Glucose Metabolism Disorders (5) · Vascular Diseases (5) · Diabetes Mellitus (4) · Pathological Conditions, Signs and Symptoms (3) · Body Weight (2) · Brain Diseases (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Female Urogenital Diseases (2)
CKD-519 (5) · Rosuvastatin Calcium (5) · Drug Evaluation (4) · Niacin (4) · Atorvastatin (3) · Ezetimibe (3) · TA-8995 (3) · anacetrapib (3) · Fenofibrate (2) · MK-0524 (2) · bococizumab (2) · 1-stearoyl-d35-2-docosahexaenoyl-sn-glycero-3-phosphocholine (1) · 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acid (1) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (1) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1)
Merck Sharp & Dohme LLC (8) · AstraZeneca (7) · Chong Kun Dang Pharmaceutical (7) · AJU Pharm Co., Ltd. (3) · Korea United Pharm. Inc. (3) · Pfizer (3) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Kowa Research Institute, Inc. (2) · Tanabe Pharma Corporation (2) · Addpharma Inc. (1) · Bristol-Myers Squibb (1) · C. T. Lamont Primary Care Research Centre (1) · Catabasis Pharmaceuticals (1) · Children's Mercy Hospital Kansas City (1) · Eli Lilly and Company (1)
United States (20) · South Korea (15) · United Kingdom (4) · China (2) · Australia (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Japan (1) · Moldova (1)
David Han, MD (2) · Min-Su Park, Ph.D (2) · Allan Gordon, MD, PhD (1) · Ashley Brooks (1) · Clare E Liddy, MD, MSc (1) · Ji Young Kim, MD, PhD (1) · Jon B Wagner, DO (1) · Lukasz Biernat, M.D (1) · Michael H Davidson, MD,FACC (1) · Mingul Kim, MD (1)
PMID 24782116, PMID 28181260, PMID 37994400, PMID 38504437, PMID 20457158, PMID 21952084, PMID 22008366, PMID 22970753, PMID 26510577, PMID 27596224, PMID 28271017, PMID 28279967, PMID 28729361, PMID 28982667, PMID 29037448, PMID 38970537, PMID 42137960
K23HL091130 (1), R01HL108160 (1)